How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Armstrong
David
D
D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic / Q000009:adverse effects; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000941:ethics; D035081:Editorial Policies; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D017712:Peer Review, Research / Q000592:standards; D010506:Periodicals as Topic / Q000191:economics / Q000592:standards*; D015871:Scientific Misconduct; D013450:Sulfones / Q000009:adverse effects*
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib